-
12 March 2026
-
12 March 2026
Ipsen appoints Michelle C. Werner as EVP, President of North America
PARIS, FRANCE, 12 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle will serve on the Executive Leadership T...
-
06 June 2023
-
06 June 2023
Ipsen and Medetia join forces to accelerate early research in rare disease
In keeping with Ipsen’s drive to accelerate the research and development of transformative therapies, we are pleased to announce a new research collaboration agreement with Medetia, a biotech with extensive drug discovery and medicinal chemistry experie...
-
25 August 2025
-
25 August 2025
Ipsen SMS Program Terms of Use
IPSEN SMS Communications:...
-
23 October 2025
-
23 October 2025
-
15 April 2024
- 3 mins read
-
15 April 2024
- 3 mins read
Mighty bonds: Leaning on others living with FOP
Carli and Erin, cross-country best friends, discuss how they’ve realized the importance of a strong support network of immediate family and friends, along with people who have a shared experience of living with FOP. Their connections have been key to nav...
-
31 August 2023
- 2 mins read
-
31 August 2023
- 2 mins read
Life with FOP: Savannah’s Story
Savannah – or Sassy Savvy as she’s known by her family – is a caring sister, a strong-willed daughter and above all else, overfilling with creativity, happiness and laughter. Savannah is also living with a rare disease, fibrodysplasia ossificans prog...
-
24 April 2023
-
24 April 2023
Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges
Ipsen is committed to bringing innovative medicines to the rare disease community where a significant unmet need exists and innovation in treatments is lacking....
-
29 June 2023
-
29 June 2023
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
PARIS, FRANCE, 29 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted in favor of investigational palovarotene as an effect...
-
13 June 2023
-
13 June 2023
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
PARIS, FRANCE, 13 June 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has approved Bylvay® (odevixibat) for the treatment of cholestatic pruritus in patients from 12 mon...
-
07 December 2023
-
07 December 2023
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
PARIS, FRANCE, 07 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral...